Other languages Bio-Thera Solutions, Ltd.

Equities

688177

CNE100003R98

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
28.98 ^CNY	-1.80%		-11.89%	-29.73%

Mar. 25	Bio-Thera Solutions Receives IND Clearance From US FDA to Initiate a Phase II Study for BAT8006	CI
Mar. 20	Bio-Thera Solutions Grants Marketing Rights of Two Drugs to Latin American Company	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bio-Thera Solutions Receives IND Clearance From US FDA to Initiate a Phase II Study for BAT8006	Mar. 25
Bio-Thera Solutions, Ltd. Partners with SteinCares to Market Two Biosimilars in LATAM	Mar. 18
Bio-Thera Solutions, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23
Sandoz pourra distribuer aux USA un biosimilaire chinois de l'Avastin de Roche	Dec. 08
Sandoz-Partner erhält US-Zulassung für Biosimilar für Roche-Blockbuster	Dec. 08
FDA Approves Bio-Thera Solutions' Avzivi (Bevacizumab-Tnjn), A Biosimilar Referencing Avastin	Dec. 07
Bio-Thera Solutions Announces Positive Results from Phase 3 Study of BAT2206, a Proposed Biosimilar Referencing Stelara	Nov. 29
Bio-Thera Solutions, Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26
Roche, Biogen Settle US Patent Infringement Case Over Actemra Biosimilar	23-10-23
Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug	23-10-23
FDA Approves Bio-Thera Solutions, Ltd.'s Partner Biogen Receives Notification from the United States Food and Drug Administration	23-10-08
Biogen Says US FDA Approves Tocilizumab Biosimilar Tofidence	23-09-29
Bio-Thera Solutions, Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24
Bio-Thera Solutions, Ltd. Announces Positive Phase 1 Clinical Data for Bat8006 (Folate-Receptor-A-Adc) and Presents Phase 1 Dose Escalation Study At the Bethune Obstetrics and Gynecology Forum	23-08-12
Bio-Thera Solutions Expands Partnership with Biomm in Brazil with Addition of BAT2206, A Stelara Biosimilar	23-06-16
Bio-Thera Solutions, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8008, an Antibody-Drug Conjugate Targeting Trop2 for the Treatment of Advanced Solid Tumors	23-03-08
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8010, an Antibody Drug Conjugate Targeting HER2 for the Treatment of Advanced Solid Tumors	23-03-06
China NMPA Approves Bio-Thera Solutions' BAT1806, A Biosimilar to Actemra(R) (Tocilizumab)	23-01-16
Biogen Says FDA Accepted Arthritis Drug Candidate Application for Review	22-12-09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Bio-Thera Solutions, Ltd.

Equities

688177

CNE100003R98

Other languages

Filters